India · Delayed Price · Currency is INR Gland Pharma Statistics
Total Valuation
Gland Pharma has a market cap or net worth of INR 412.37 billion. The enterprise value is 381.61 billion.
| Market Cap | 412.37B |
| Enterprise Value | 381.61B |
Important Dates
The next confirmed earnings date is Monday, August 10, 2026.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | Aug 11, 2026 |
Share Statistics
| Current Share Class | 164.76M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.13% |
| Shares Change (QoQ) | +0.11% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 36.39% |
| Float | 79.36M |
Valuation Ratios
The trailing PE ratio is 40.14 and the forward PE ratio is 33.47.
| PE Ratio | 40.14 |
| Forward PE | 33.47 |
| PS Ratio | 6.41 |
| PB Ratio | 3.98 |
| P/TBV Ratio | 4.14 |
| P/FCF Ratio | 76.28 |
| P/OCF Ratio | 39.98 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 23.64, with an EV/FCF ratio of 70.59.
| EV / Earnings | 37.15 |
| EV / Sales | 5.93 |
| EV / EBITDA | 23.64 |
| EV / EBIT | 32.05 |
| EV / FCF | 70.59 |
Financial Position
The company has a current ratio of 4.68, with a Debt / Equity ratio of 0.03.
| Current Ratio | 4.68 |
| Quick Ratio | 3.41 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.18 |
| Debt / FCF | 0.52 |
| Interest Coverage | 40.28 |
Financial Efficiency
Return on equity (ROE) is 10.53% and return on invested capital (ROIC) is 12.20%.
| Return on Equity (ROE) | 10.53% |
| Return on Assets (ROA) | 6.27% |
| Return on Invested Capital (ROIC) | 12.20% |
| Return on Capital Employed (ROCE) | 10.92% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 14.78M |
| Profits Per Employee | 2.36M |
| Employee Count | 4,351 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 1.50 |
Taxes
In the past 12 months, Gland Pharma has paid 4.37 billion in taxes.
| Income Tax | 4.37B |
| Effective Tax Rate | 29.86% |
Stock Price Statistics
The stock price has increased by +21.81% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +21.81% |
| 50-Day Moving Average | 2,365.50 |
| 200-Day Moving Average | 1,930.02 |
| Relative Strength Index (RSI) | 58.12 |
| Average Volume (20 Days) | 55,062 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Gland Pharma had revenue of INR 64.31 billion and earned 10.27 billion in profits. Earnings per share was 62.28.
| Revenue | 64.31B |
| Gross Profit | 37.97B |
| Operating Income | 11.91B |
| Pretax Income | 14.65B |
| Net Income | 10.27B |
| EBITDA | 15.97B |
| EBIT | 11.91B |
| Earnings Per Share (EPS) | 62.28 |
Balance Sheet
The company has 33.59 billion in cash and 2.84 billion in debt, with a net cash position of 30.76 billion.
| Cash & Cash Equivalents | 33.59B |
| Total Debt | 2.84B |
| Net Cash | 30.76B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 103.58B |
| Book Value Per Share | 628.68 |
| Working Capital | 59.18B |
Cash Flow
In the last 12 months, operating cash flow was 10.31 billion and capital expenditures -4.91 billion, giving a free cash flow of 5.41 billion.
| Operating Cash Flow | 10.31B |
| Capital Expenditures | -4.91B |
| Depreciation & Amortization | 4.24B |
| Net Borrowing | -880.62M |
| Free Cash Flow | 5.41B |
| FCF Per Share | n/a |
Margins
Gross margin is 59.05%, with operating and profit margins of 18.51% and 15.98%.
| Gross Margin | 59.05% |
| Operating Margin | 18.51% |
| Pretax Margin | 22.77% |
| Profit Margin | 15.98% |
| EBITDA Margin | 24.84% |
| EBIT Margin | 18.51% |
| FCF Margin | 8.41% |
Dividends & Yields
This stock pays an annual dividend of 20.00, which amounts to a dividend yield of 0.80%.
| Dividend Per Share | 20.00 |
| Dividend Yield | 0.80% |
| Dividend Growth (YoY) | 11.11% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 28.87% |
| Buyback Yield | -0.13% |
| Shareholder Yield | 0.67% |
| Earnings Yield | 2.49% |
| FCF Yield | 1.31% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Gland Pharma is 2,325.29, which is -7.15% lower than the current price. The consensus rating is "Buy".
| Price Target | 2,325.29 |
| Price Target Difference | -7.15% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 14.05% |
| EPS Growth Forecast (3Y) | 20.17% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Gland Pharma has an Altman Z-Score of 10.4 and a Piotroski F-Score of 8.
| Altman Z-Score | 10.4 |
| Piotroski F-Score | 8 |